Wolfe Research analyst Andy Chen downgraded 89bio (ETNB) to Peer Perform from Outperform without a price target after the company entered into an agreement to be acquired by Roche (RHHBY) for $14.50 per share in cash, plus a non-tradeable contingent value right to receive certain milestone payments of up to an aggregate of $6.00 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETNB: